Abstract
Licorice, the dried root or stolon of Glycyrrhiza glabra or G. ularensis, is commonly used worldwide as a food sweetener or crude drug. Its major ingredient is glycyrrhizin. Hypokalemia or pseudoaldosteronism (PsA) is one of the most frequent side effects of licorice intake. Glycyrrhizin metabolites inhibit type 2 11β-hydroxysteroid dehydrogenase (11βHSD2), which decomposes cortisol into inactive cortisone in the distal nephron, thereby inducing mineralocorticoid receptor activity. Among the several reported glycyrrhizin-metabolites, 18β-glycyrrhetyl-3-O-sulfate is the major compound found in humans after licorice consumption, followed by glycyrrhetinic acid. These metabolites are highly bound to albumin in blood circulation and are predominantly excreted into bile via multidrug resistance-associated protein 2 (Mrp2). High dosage and long-term use of licorice are constitutional risk factors for PsA. Orally administered glycyrrhizin is effectively hydrolyzed to glycyrrhetinic acid by the intestinal bacteria in constipated patients, which enhances the bioavailability of glycyrrhizin metabolites. Under hypoalbuminemic conditions, the unbound metabolite fractions can reach 11βHSD2 at the distal nephron. Hyper direct-bilirubin could be a surrogate marker of Mrp2 dysfunction, which results in metabolite accumulation. Older age is associated with reduced 11βHSD2 function, and several concomitant medications, such as diuretics, have been reported to affect the phenotype. This review summarizes several factors related to licorice-induced PsA, including daily dosage, long-term use, constipation, hypoalbuminemia, hyper direct-bilirubin, older age, and concomitant medications.
Introduction
Licorice, the dried root or stolon of Glycyrrhiza glabra or G. ularensis, is commonly used as a food sweetener or crude drug worldwide. Wide-range pharmaceutical effectiveness of licorice includes anti-ulcer, anti-spasmodic, anti-inflammatory, anti-oxidative, anti-virus, anti-microbial, anti-carcinogenic, and anti-androgenic properties (1). Pseudoaldosteronism (PsA) is, however, one of the most frequent side effects of licorice intake and has been well described by Conn et al. (2). The clinical presentation of PsA is similar to that of primary aldosteronism and is characterized by peripheral edema, hypertension, laboratory hypokalemia, and lower plasma renin activity, due to the excessive action of mineralocorticoid receptors. The mineralocorticoid receptor stabilizes epithelial sodium channels on the apical side of the cortical collecting duct principal cell, which increases sodium reabsorption, corresponding to peripheral edema, hypertension, and lower plasma renin activity (Figure 1), whereas potassium is excreted as a cationic ion via the renal outer medullary potassium channel, which results in hypokalemia and, in severe cases, myopathy or arrhythmia (1). Most cases of licorice-induced PsA are self-limiting and are resolved once licorice intake ceases, without any specific treatment. However, some cases can progress to severe hypokalemia and life-threatening arrhythmia (3).
Figure 1
Pathophysiology of Licorice-Induced PsA
Licorice contains glycyrrhizin (GL), a glycoside of glycyrrhetinic acid (GA) containing two molecules of glucuronic acid. Licorice has long been known to exert corticosteroid-like action, and GL and GA are considered to cause PsA by binding to mineralocorticoid receptors (2). However, their affinity for the receptor is significantly lower than that of the original substrate, aldosterone (4, 5), and the hypothesis that it acts by directly binding to the receptor at the actual blood concentrations of GL and GA is unrealistic (1). Furthermore, previous studies found that licorice-induced PsA did not occur in patients and animals with adrenal deficiency who had lower blood cortisol levels (6–10).
Cortisol, an adrenocortical hormone, has the same affinity for mineralocorticoid receptors as aldosterone; however, it occurs at a higher concentration in the blood. Cortisol is then decomposed by type 2 11β-hydroxysteroid dehydrogenase (11βHSD2) in renal tubule cell cytoplasm into cortisone, which has a lower affinity for the receptor (11), especially at the distal nephron (12, 13) in the normal state. Inhibition of 11βHSD2 by GL metabolites, rather than direct binding of GL or its metabolites to mineralocorticoid receptors was thus considered as the mechanism of licorice-induced PsA (14–16). With GL metabolites in the 11βHSD2-expressing cells, inhibition of 11βHSD2 results in a higher concentration of cortisol that binds to and stimulates the mineralocorticoid receptor (Figure 1). Therefore, the difference between primary aldosteronism and PsA is the plasma aldosterone concentration, which is lower in PsA and higher in primary aldosteronism. The aldosterone concentration is suppressed by negative feedback in licorice-induced PsA, even though aldosterone metabolism in the liver could be suppressed by GL or GA (17).
There are several other causes of PsA, including enzymatic defects in adrenal steroidogenesis (deficiency of 17α-hydroxylase and 11β-hydroxylase), gain-of-function mutations in the mineralocorticoid receptor (18), saturation of mineralocorticoid receptor binding by cortisol (Cushing syndrome), alterations in 11βHSD2 (syndrome of apparent mineralocorticoid excess), and genetic alterations in sodium channel expression (Liddle syndrome) or the sodium-chloride co-transporter (Gordon syndrome) (19).
GL-Metabolites That Truly Reach and Inhibit Type 2 11β-Hydroxysteroid Dehydrogenase
When GL is administered orally, it cannot be absorbed in its original form owing to its molecular structure, which contains both hydrophobic and hydrophilic parts. Orally ingested GL is hydrolyzed to GA by the intestinal bacteria (20–24), and GA appears as the main metabolite in blood circulation (20). Both GA and GL inhibit 11βHSD2 in vitro, but the inhibitory activity of GA is approximately 200 times higher than that of GL (15). Further, as GL does not appear in blood after licorice ingestion, GA has been considered as the causative agent for the onset of licorice-induced PsA that inhibits 11βHSD2 in humans. However, the plasma concentration of 3-monoglucuronyl glycyrrhetinic acid (3MGA) was reported to be significantly higher in patients with hypokalemia than in those with normokalemia and chronic hepatitis who had been orally treated with GL for more than four weeks, even though the plasma concentration of GA did not differ between the two groups (25). When GL is injected intravenously into rats, it is partially metabolized to 3MGA in the liver by lysosomal β-D-glucuronidase, after which GL and 3MGA are excreted with bile (26). Although 3MGA did not appear in the blood circulation and urine of normal Sprague-Dawley rats that were orally treated with GA, it was found in the blood and urine of multidrug resistance-associated protein (Mrp) 2-deficient Eisai hyperbilirubinuric rats (EHBR) (27). Both GA and 3MGA have high affinity for albumin (28–31); however, only 3MGA is the substrate of organic anion transporter (OAT) 1 and OAT3, which are expressed at the basolateral membrane of renal tubular epithelial cells (31). As a substrate of basolateral transporters, 3MGA is compatible with the intracellular space where 11βHSD2 is located, and is considered a causative agent of PsA. However, 3MGA has not been detected by mass spectrometry in humans after licorice intake (32–34). Instead, we isolated and identified 22α-hydroxy-18β-glycyrrhetyl-3-O-sulfate-30-glucuronide (compound 1), 22α-hydroxy-18β-glycyrrhetyl-3-O-sulfate (compound 2), 18β-glycyrrhetyl-3-O-sulfate (compound 3, GA3S), and 18β-glycyrrhetyl-3-O-sulfate-30-glucuronide (compound 4) as other GL metabolites in the urine of EHBR orally treated with GA (34–36). We also found that the blood and urinary concentrations of these new metabolites were much higher than those of 3MGA in EHBR orally treated with GA, and that their pharmacokinetic behavior was similar to that of 3MGA (34, 35). In humans, GA3S was detected at the highest concentration in the blood of patients with PsA who developed rhabdomyolysis due to licorice (34). Further, there were no cases where compound 1 was detected, while compound 2, GL, and 3MGA were rarely detected. The concentration of GA3S was still the highest, followed by GA and compound 4 in the serum of patients in a multicenter retrospective case series of milder PsA (33, 36). Therefore, we considered GA3S to be the most likely causative agent of PsA.
Diagnosis of Licorice-Induced PsA
There is no concrete diagnostic criterion for licorice-induced PsA, and diagnosis is purely based on the clinical presentation of patients during licorice intake rather than by measuring the GL metabolite accumulation in blood. Therefore, diagnosing PsA is challenging, especially in mild cases. The serum concentrations of GA3S, GA, and compound 4 were found to be negatively correlated with serum potassium concentration, plasma renin activity, and aldosterone concentration (33, 36). From these results, it is suggested that such GL-metabolites could be used as an objective laboratory marker of “licorice-induced” PsA, and could be applied to the early detection and prevention of licorice-induced PsA especially in high risk patients.
As it is difficult to diagnose PsA based only on physical examination, including peripheral edema and hypertension, laboratory testing of parameters such as potassium and aldosterone levels is needed. The grade or occurrence of peripheral edema and hypertension in patients who consumed licorice did not correlate well with laboratory abnormalities, such as hypokalemia, low renin activity, aldosterone concentration, and GL metabolites (33, 36). Several studies have shown the expression of mineralocorticoid receptor and 11βHSD1/2 in the heart and arteries (37–39). Inhibition of 11βHSD2 resulted in an increased contractile response to phenylephrine (40) and altered endothelium-dependent relaxation of arteries due to decreased endothelial nitric oxide and increased endothelin-1 (41). These observations suggest that renal sodium reabsorption cannot fully explain hypertension in licorice-induced PsA.
Clinical Risk Factors for Licorice-Induced PsA
Pharmacokinetics
Daily Dosage
The daily dosage of licorice is a reasonable risk factor for licorice-induced PsA (42, 43). Of the 147 oral Kampo medicinal products for ethical use in Japan, 109 (74%) contain extracts with 1.0–8.0 g licorice for daily dose. Their package inserts describe hypertension, hypokalemia, arrhythmia, and rhabdomyolysis as adverse events of licorice-induced PsA. Kampo medicinal products containing more than or equal to 2.5 g licorice daily are contraindicated in patients with aldosteronism, myopathy, or hypokalemia, and those containing <2.5 g licorice daily still indicate these PsA-related conditions as potential side effects. As 74% of Kampo medicinal products contain GL, the use of multiple Kampo medicinal products can result in excessive GL ingestion, especially if the medicines are prescribed in multiple hospitals and clinics simultaneously.
Long-Term Use
Long-term use (>30 days) is also an important factor for developing licorice-induced PsA and related symptoms. In a retrospective cohort study, more than 80% of patients developed licorice-induced PsA and related symptoms, including hypokalemia in elderly patients (>60 years old) who received shakuyakukanzoto, which contains 6.0 g licorice, for longer than 30 days (44). This observation in the study is reasonable as the inhibition of 11βHSD plateaued after 2 weeks of GL ingestion (45).
Absorption
Constipation
When GL is administered orally, it is hydrolyzed to GA by the intestinal bacteria (20) and then absorbed into blood (Figure 2). GA3S, a sulfate conjugate of GA which is excreted via bile, is also hydrolyzed to GA by the intestinal bacteria and is then partially absorbed from the intestine into the blood circulation to exhibit enterohepatic circulation. The unabsorbed portions of GA and GA3S are then excreted in the feces. Thus, large individual variations in the blood concentration of GA were found even at the same dosage of GL or licorice. This variation may be due to the difference in the activity of hydrolyzed GL in the intestinal bacterial flora among the subjects. The hydrolyzation ratio also depends on the residence time of GL in the intestinal tract. The longer GL stays in the intestinal tract, the more it is hydrolyzed by bacterial β-glucuronidase, resulting in a higher serum concentration of GA (46).
Figure 2
Distribution
As GL metabolites are highly bound to serum albumin (>99.9%) in blood circulation (47, 48), they are not excreted in urine through glomerular filtration. However, they can be transported from blood circulation into tubular cells via OAT1 and OAT3, or other transporters and can participate in the inhibition of intracellular 11βHSD2 as well as their unbound forms (33–35). Hypoalbuminemia increases the unbound fraction of metabolites in blood circulation (30), resulting in enhanced distribution into principal cells where 11β-HSD2 is located (Figure 1). Therefore, hypoalbuminemia may be an important risk factor for PsA. Indeed, hypoalbuminemia has been identified as a risk factor in patients receiving yokukansan, which contains 1.5 g of licorice daily (49), as well as in other case series (50, 51).
Metabolism
To the best of our knowledge, there are no reports describing an individual variety of primary or secondary metabolism of GA in humans. We have previously reported that GA is conjugated by human liver sulfotransferase 2A1 (dehydroepiandrosterone sulfotransferase) into GA3S at C-3 (Figure 2). As serum concentrations of GA and GA3S correlated well, regardless of sex, sulfate conjugation is suggested to have a limited impact on inter-individual variation in GA pharmacokinetics (33).
Excretion
When bile excretion of GA3S is suppressed due to Mrp2 dysfunction (Figure 2), GA3S is transferred into the blood circulation. We have previously highlighted the involvement of Mrp2 in the biliary excretion of GL metabolites in rats (27, 34, 35) and possibly in humans (50, 51). GL metabolites significantly accumulate in the EHBR (27, 34, 35). While this phenomenon is still controversial in humans, we reported the co-occurrence of hypokalemia and hyperbilirubinemia, which could be a surrogate marker for MRP2 dysfunction in several cases; further, hypokalemia was found to be more common in patients with hyperbilirubinemia (50, 51). We consider hyper direct-bilirubin as a rare risk factor for licorice-induced PsA when compared with hypoalbuminemia, which is more common in outpatient settings (51).
Other Factors
Age
Older age may affect several processes of GL metabolism, and licorice-induced PsA is common in elderly patients (43, 52). As age-dependent decrease in 11 βHSD2 activity in hypertensive patients has been reported (53), alteration in enzyme activity in aging is another risk factor for elderly subjects (Figure 1). In addition, elevation of serum cortisol concentrations occur in elderly which may be associated with decreased negative feedback at the hippocampus related to decreased glucocorticoid receptor concentration (54). This phenomenon could result in the inhibition of 11βHSD2 and also explains why licorice-induced PsA is common among elderly patients. To the best of our knowledge, there is no case report of licorice-induced PsA in pediatric patients meaning that licorice and GL is safe to use in children.
Female Sex
Several other factors have been proposed as risk factors for licorice-induced PsA, including female sex (55, 56), lower body weight (43), and reduced body surface area (57), which have not been well explained and might be confounding factors (52). Theoretically, constipation is common in female patients, and the higher dosage administered despite lower body weight and surface area compared with that in male patients even with the same daily dosage of licorice.
Concomitant Use of Medications
Concomitant use of medications, including antihypertensives, especially thiazide, loop diuretics, aldosterone blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers, affects the phenotype of PsA. For example, concomitant use of potassium-losing diuretics increases the risk of hypokalemia in patients treated with yokukansan, an extract prepared with 1.5 g licorice (43, 49). Loop diuretics block Na-K-2Cl cotransporters, and thiazides block Na-Cl transporters in the distal nephron. Although these diuretics can prevent peripheral edema and hypertension, they increase intraductal flow into the collecting duct and stimulate sodium reabsorption (58), which increases potassium excretion and induces hypokalemia in patients taking licorice-containing products. Systemic glucocorticoid use can also aggravate the inhibition of 11βHSD2 that is similar to Cushing syndrome.
Conversely, potassium-sparing medications such as aldosterone blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers prevent licorice-induced hypokalemia. Concomitant use of these medications thus hinders the early detection of licorice-induced PsA.
Dementia
Dementia also makes early detection of PsA difficult (43). Therefore, medical specialists, including pharmacists and nurses, should be aware of hypertension or peripheral edema in the patient, even though these physical signs are not very sensitive or specific for licorice-induced PsA.
Conclusions
We summarized the current understanding regarding the pathophysiology of licorice-induced PsA and listed several factors that affect the pharmacokinetics of GL metabolites, including the daily dosage, dosing period, constipation, hypoalbuminemia, and hyperdirect-bilirubin. Further, older age and several concomitant medications are risk factors for licorice-induced pseudoaldosteronism. Importantly, a deep understanding of the crude drugs in Kampo preparations and the pathophysiology of licorice-induced PsA is necessary for the prevention and early diagnosis of PsA. Clinicians should be aware of PsA and balance the merit and demerit of using licorice or GL for therapy.
Funding
This work was supported by a Grant-in-Aid from the Research Project for Improving Quality in Healthcare and Collecting Scientific Evidence on Integrative Medicine from AMED under grant numbers JP17lk0310036h0001, JP18lk0310049h0001, and JP19lk0310064h0001. The authors declare that this study received funding from Tsumura Co. In addition, TM received research grant supports from Tsumura & Co., Kracie Pharmaceuticals, JPS Pharmaceuticals, and Taisho Pharmaceutical Holdings. MM received research grant supports from Tsumura & Co. and Kracie Pharmaceuticals. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of article, or the decision to submit it for publication. An article processing charge, English editing, and figure drawing fee of this article were payed by the joint research program fund of Keio University and Tsumura Co.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
TY, SS, MH, and TM wrote the draft of the manuscript. MM and KW designed the study and revised the manuscript. All authors read and approved the final manuscript.
Acknowledgments
We thank Drs. Kan'ichiro Ishiuch, Osamu Morinaga, Kiyoshi Minamizawa, Keiko Ogawa-Ochiai, Takao Namiki, and Tomonori Nakamura for identifying new GL metabolites, providing human samples, and helpful discussions. We thank the Japan Agency for Medical Research and Development (AMED) for data analysis and presentation, and for providing the research support.
Conflict of interest
TY is employed for the joint research program with Tsumura & Co. KW and MH received lecture fee from Tsumura & Co. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past collaboration with several of the authors TY, TM, and KW at the time of review.
References
1.
DeutchMRGrimmDWehlandMInfangerMKrugerM. Bioactive candy: effects of licorice on the cardiovascular system. Foods. (2019) 8:495. 10.3390/foods8100495
2.
ConnJWRovnerDRCohenEL. Licorice-induced pseudoaldosteronism. Hypertension, hypokalemia, aldosteronopenia, and suppressed plasma renin activity. JAMA. (1968) 205:492–6. 10.1001/jama.205.7.492
3.
EdelmanERButalaNMAveryLLLundquistALDigheAS. Case 30-2020: a 54-year-old man with sudden cardiac arrest. N Engl J Med. (2020) 383:1263–75. 10.1056/NEJMcpc2002420
4.
UlmannAMenardJCorvolP. Binding of glycyrrhetinic acid to kidney mineralocorticoid and glucocorticoid receptors. Endocrinology. (1975) 97:46–51. 10.1210/endo-97-1-46
5.
ArmaniniDKarbowiakIFunderJW. Affinity of liquorice derivatives for mineralocorticoid and glucocorticoid receptors. Clin Endocrinol. (1983) 19:609–12. 10.1111/j.1365-2265.1983.tb00038.x
6.
MolhuysenJAGerbrandyJde VriesLAde JongJCLenstraJBTurnerKPet al. A liquorice extract with deoxycortone-like action. Lancet. (1950) 2:381–6. 10.1016/S0140-6736(50)91341-9
7.
BorstJGTen HoltSPDe VriesLAMolhuysenJA. Synergistic action of liquorice and cortisone in Addison's and Simmonds's disease. Lancet. (1953) 1:657–63. 10.1016/S0140-6736(53)91800-5
8.
CardWIMitchellWStrongJATaylorNRTompsettSLWilsonJM. Effects of liquorice and its derivatives on salt and water metabolism. Lancet. (1953) 1:663–8. 10.1016/S0140-6736(53)91801-7
9.
ElmadjianFHopeJMPincusG. The action of mono-ammonium glycyrrhizinate on adrenalectomized subjects and its synergism with hydrocortisone. J Clin Endocrinol Metab. (1956) 16:338–49. 10.1210/jcem-16-3-338
10.
GirerdRJRassaertCLDipasqualeGKrocRL. Endocrine involvement in licorice hypertension. Am J Physiol. (1960) 198:718–20. 10.1152/ajplegacy.1960.198.4.718
11.
EdwardsCR. Renal 11-β-hydroxysteroid dehydrogenase: a mechanism ensuring mineralocorticoid specificity. Horm Res. (1990) 34:114–7. 10.1159/000181808
12.
RolandBLFunderJW. Localization of 11β-hydroxysteroid dehydrogenase type 2 in rat tissues: in situ studies. Endocrinology. (1996) 137:1123–8. 10.1210/endo.137.3.8603583
13.
Naray-Fejes-TothAFejes-TothG. Extranuclear localization of endogenous 11β-hydroxysteroid dehydrogenase-2 in aldosterone target cells. Endocrinology. (1998) 139:2955–9. 10.1210/endo.139.6.6036
14.
StewartPMWallaceAMValentinoRBurtDShackletonCHEdwardsCR. Mineralocorticoid activity of liquorice: 11-β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. (1987) 2:821–4. 10.1016/S0140-6736(87)91014-2
15.
MonderCStewartPMLakshmiVValentinoRBurtDEdwardsCR. Licorice inhibits corticosteroid 11β-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology. (1989) 125:1046–53. 10.1210/endo-125-2-1046
16.
TanahashiTMuneTMoritaHTanahashiHIsomuraYSuwaTet al. Glycyrrhizic acid suppresses type 2 11β-hydroxysteroid dehydrogenase expression in vivo. J Steroid Biochem Mol Biol. (2002) 80:441–7. 10.1016/S0960-0760(02)00033-X
17.
LatifSAConcaTJMorrisDJ. The effects of the licorice derivative, glycyrrhetinic acid, on hepatic 3 α- and 3β-hydroxysteroid dehydrogenases and 5α and 5β-reductase pathways of metabolism of aldosterone in male rats. Steroids. (1990) 55:52–8. 10.1016/0039-128X(90)90024-6
18.
ZennaroMCFernandes-RosaF. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor mutations. J Endocrinol. (2017) 234:T93–106. 10.1530/JOE-17-0089
19.
SabbadinCArmaniniD. Syndromes that mimic an excess of mineralocorticoids. High Blood Press Cardiovasc Prev. (2016) 23:231–5. 10.1007/s40292-016-0160-5
20.
AkaoTHayashiTKobashiKKanaokaMKatoHKobayashiMet al. Intestinal bacterial hydrolysis is indispensable to absorption of 18 β-glycyrrhetic acid after oral administration of glycyrrhizin in rats. J Pharm Pharmacol. (1994) 46:135–7. 10.1111/j.2042-7158.1994.tb03756.x
21.
KimDHHongSWKimBTBaeEAParkHYHanMJ. Biotransformation of glycyrrhizin by human intestinal bacteria and its relation to biological activities. Arch Pharm Res. (2000) 23:172–7. 10.1007/BF02975509
22.
KimDHLeeSWHanMJ. Biotransformation of glycyrrhizin to 18β-glycyrrhetinic acid-3-O-β-D-glucuronide by streptococcus LJ-22, a human intestinal bacterium. Biol Pharm Bull. (1999) 22:320–2. 10.1248/bpb.22.320
23.
AkaoT. Purification and characterization of glycyrrhetic acid mono-glucuronide β-D-glucuronidase in Eubacterium sp. GLH Biol Pharm Bull. (1999) 22:80–2. 10.1248/bpb.22.80
24.
HattoriMSakamotoTYamagishiTSakamotoKKonishiKKobashiKet al. Metabolism of glycyrrhizin by human intestinal flora. II Isolation and characterization of human intestinal bacteria capable of metabolizing glycyrrhizin and related compounds. Chem Pharm Bull. (1985) 33:210–7. 10.1248/cpb.33.210
25.
KatoHKanaokaMYanoSKobayashiM. 3-Monoglucuronyl-glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. J Clin Endocrinol Metab. (1995) 80:1929–33. 10.1210/jc.80.6.1929
26.
AkaoTAkaoTHattoriMKanaokaMYamamotoKNambaTet al. Hydrolysis of glycyrrhizin to 18 beta-glycyrrhetyl monoglucuronide by lysosomal β-D-glucuronidase of animal livers. Biochem Pharmacol. (1991) 41:1025–9. 10.1016/0006-2952(91)90210-V
27.
MakinoTOhtakeNWatanabeATsuchiyaNImamuraSIizukaSet al. Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury. Drug Metab Dispos. (2008) 36:1438–43. 10.1124/dmd.108.021089
28.
IchikawaTIshidaSSakiyaYSawadaY. Binding of glycyrrhizin to rat plasma and rat serum albumin. Chem Pharm Bull. (1985) 33:3031–3. 10.1248/cpb.33.3031
29.
IshidaSIchikawaTSakiyaY. Binding of glycyrrhetinic acid to rat plasma, rat serum albumin, human serum, and human serum albumin. Chem Pharm Bull. (1988) 36:440–3. 10.1248/cpb.36.440
30.
KogaKTomoyamaMOhyanagiKTakadaK. Pharmacokinetics of glycyrrhizin in normal and albumin-deficient rats. Biopharm Drug Dispos. (2008) 29:373–81. 10.1002/bdd.619
31.
MakinoTOkajimaKUebayashiROhtakeNInoueKMizukamiH. 3-Monoglucuronyl-glycyrrhretinic acid is a substrate of organic anion transporters expressed in tubular epithelial cells and plays important roles in licorice-induced pseudoaldosteronism by inhibiting 11β-hydroxysteroid dehydrogenase 2. J Pharmacol Exp Ther. (2012) 342:297–304. 10.1124/jpet.111.190009
32.
SadakaneCWatanabeJFukutakeMNisimuraHMaemuraKKaseYet al. Pharmacokinetic profiles of active components after oral administration of a Kampo medicine, Shakuyakukanzoto, to healthy adult Japanese volunteers. J Pharm Sci. (2015) 104:3952–9. 10.1002/jps.24596
33.
TakahashiKYoshinoTMakiYIshiuchiKNamikiTOgawa-OchiaiKet al. Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism: a multi-centre cross-sectional study. Arch Toxicol. (2019) 93:3111–9. 10.1007/s00204-019-02588-2
34.
IshiuchiKMorinagaOOhkitaTTianCHirasawaAMitamuraMet al. 18β-glycyrrhetyl-3-O-sulfate would be a causative agent of licorice-induced pseudoaldosteronism. Sci Rep. (2019) 9:1587. 10.1038/s41598-018-38182-2
35.
MorinagaOIshiuchiKOhkitaTTianCHirasawaAMitamuraMet al. Isolation of a novel glycyrrhizin metabolite as a causal candidate compound for pseudoaldosteronism. Sci Rep. (2018) 8:15568. 10.1038/s41598-018-33834-9
36.
IshiuchiKiMorinagaOYoshinoTMitamuraMHirasawaAMakiYet al. Identification of an alternative glycyrrhizin metabolite causing liquorice-induced pseudohyperaldosteronism and the development of ELISA system to detect the predictive biomarker. Front Pharmacol. (2021) 12:688508. 10.3389/fphar.2021.688508
37.
LombesMAlfaidyNEugeneELessanaAFarmanNBonvaletJP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase in the human heart. Circulation. (1995) 92:175–82. 10.1161/01.CIR.92.2.175
38.
HadokePWChristyCKotelevtsevYVWilliamsBCKenyonCJSecklJRet al. Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11β-hydroxysteroid dehydrogenase. Circulation. (2001) 104:2832–7. 10.1161/hc4801.100077
39.
ChristyCHadokePWPatersonJMMullinsJJSecklJRWalkerBR. 11β-hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension. (2003) 42:580–7. 10.1161/01.HYP.0000088855.06598.5B
40.
SounessGWBremASMorrisDJ. 11β-Hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism. Steroids. (2002) 67:195–201. 10.1016/S0039-128X(01)00148-9
41.
QuaschningTRuschitzkaFShawSLuscherTF. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension. (2001) 37:801–5. 10.1161/01.HYP.37.2.801
42.
MantaniNOkaHSahashiYSuzukiAAyabeMSuzukiMet al. Relationship between incidence of pseudoaldosteronism and daily dose of Glycyrrhiza: review of the literature. Kampo Med. (2015) 66:197–202. 10.3937/kampomed.66.197
43.
IshidaTKawadaKMorisawaSJobuKMoritaYMiyamuraM. Risk factors for pseudoaldosteronism with Yokukansan use: analysis using the Japanese adverse drug report (JADER) database. Biol Pharm Bull. (2020) 43:1570–6. 10.1248/bpb.b20-00424
44.
HommaMIshiharaMQianWKohdaY. Effects of long term administration of Shakuyaku-kanzo-To and Shosaiko-To on serum potassium levels. Yakugaku Zasshi. (2006) 126:973–8. 10.1248/yakushi.126.973
45.
PloegerBMensingaTSipsADeerenbergCMeulenbeltJDeJonghJet al. population physiologically based pharmacokinetic/pharmacodynamic model for the inhibition of 11-β-hydroxysteroid dehydrogenase activity by glycyrrhetic acid. Toxicol Appl Pharmacol. (2001) 170:46–55. 10.1006/taap.2000.9078
46.
PloegerBMensingaTSipsAMeulenbeltJDeJonghJ. A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling. Pharm Res. (2000) 17:1516–25. 10.1023/A:1007661209921
47.
MakinoT. 3-Monoglucuronyl glycyrrhretinic acid is a possible marker compound related to licorice-induced pseudoaldosteronism. Biol Pharm Bull. (2014) 37:898–902. 10.1248/bpb.b13-00997
48.
IshidaSSakiyaYIchikawaTKinoshitaMAwazuS. Binding of glycyrrhizin to human serum and human serum albumin. Chem Pharm Bull. (1989) 37:226–8. 10.1248/cpb.37.226
49.
ShimadaSAraiTTamaokaAHommaM. Liquorice-induced hypokalaemia in patients treated with Yokukansan preparations: identification of the risk factors in a retrospective cohort study. BMJ Open. (2017) 7:e014218. 10.1136/bmjopen-2016-014218
50.
YoshinoTNakamuraHSanoMHoribaYNakamuraTWatanabeK. Elevated direct bilirubin—possible predictors for ppeudoaldosteronism: a case-control study Tradit. Kampo Med. (2016) 3:174–6. 10.1002/tkm2.1058
51.
KomatsuAYoshinoTSuzukiTNakamuraTKanaiTWatanabeK. Risk factors associated with pseudoaldosteronism in patients with chronic hepatitis: a retrospective cohort study. Basic Clin Pharmacol Toxicol. (2018) 124:607–14. 10.1111/bcpt.13178
52.
YoshinoTYanagawaTWatanabeK. Risk factors for pseudoaldosteronism with rhabdomyolysis caused by consumption of drugs containing licorice and differences between incidence of these conditions in Japan and other countries: case report and literature review. J Alternat Complement Med. (2014) 20:516–20. 10.1089/acm.2013.0454
53.
HenschkowskiJStuckAEFreyBMGillmannGDickBFreyFJet al. Age-dependent decrease in 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) activity in hypertensive patients. Am J Hypertens. (2008) 21:644–9. 10.1038/ajh.2008.152
54.
YiallourisATsioutisCAgapidakiEZafeiriMAgouridisAPNtourakisDet al. Adrenal aging and its implications on stress responsiveness in humans. Front Endocrinol. (2019) 10:54. 10.3389/fendo.2019.00054
55.
SigurjonsdottirHAManhemKAxelsonMWallerstedtS. Subjects with essential hypertension are more sensitive to the inhibition of 11β-HSD by liquorice. J Hum Hypertens. (2003) 17:125–31. 10.1038/sj.jhh.1001504
56.
SigurjonsdottirHAAxelsonMJohannssonGManhemKNystromEWallerstedtS. The liquorice effect on the RAAS differs between the genders. Blood Press. (2006) 15:169–72. 10.1080/08037050600593060
57.
MantaniNOkaHWatanabeT. A study of factors associated with the development of pseudoaldosteronism in outpatients. J Altern Complement Med. (2020) 26:329–34. 10.1089/acm.2019.0415
58.
KashlanOBKleymanTR. Epithelial Na+ channel regulation by cytoplasmic and extracellular factors. Exp Cell Res. (2012) 318:1011–9. 10.1016/j.yexcr.2012.02.024
Summary
Keywords
Japanese Kampo medicine, licorice, pseudoaldosteronism, hypokalemia, pharmacokinetics
Citation
Yoshino T, Shimada S, Homma M, Makino T, Mimura M and Watanabe K (2021) Clinical Risk Factors of Licorice-Induced Pseudoaldosteronism Based on Glycyrrhizin-Metabolite Concentrations: A Narrative Review. Front. Nutr. 8:719197. doi: 10.3389/fnut.2021.719197
Received
02 June 2021
Accepted
16 August 2021
Published
17 September 2021
Volume
8 - 2021
Edited by
Takao Namiki, Chiba University, Japan
Reviewed by
Yukihiro Shoyama, Nagasaki International University, Japan; Charikleia Stefanaki, National and Kapodistrian University of Athens, Greece
Updates
Copyright
© 2021 Yoshino, Shimada, Homma, Makino, Mimura and Watanabe.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tetsuhiro Yoshino tetta213@keio.jp
This article was submitted to Clinical Nutrition, a section of the journal Frontiers in Nutrition
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.